Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ips Bio Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single matter is being handled within 1 distinct art unit, reflecting a very specific technical focus for the company's active patent prosecution. The presence of 1 distinct examiner suggests that the company's current success in the life sciences sector is under the review of a single official. This concentration in Biotechnology & Pharmaceuticals allows for a focused legal strategy without the need to reconcile different examiner preferences.
The busiest examiner for this portfolio is PAULUS, ERIN VIRGINIA, who is currently managing 1 pending office action. Since the company only has 1 pending office action in total, the feedback from PAULUS, ERIN VIRGINIA will be the decisive factor for the current state of the portfolio. The alignment of 1 distinct examiner with 1 distinct art unit means that the company can tailor its arguments to the specific standards of that individual and unit. Practitioners should focus on the examination history of PAULUS, ERIN VIRGINIA, as this person oversees the company's 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAULUS, ERIN VIRGINIA | 1 | 20.0% | +94.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564485 | COMPOSITION FOR PREVENTING AND TREATING STROKE, COMPRISING HLA HOMOZYGOUS INDUCED PLURIPOTENT STEM CELL-DERIVED NEURAL PRECURSOR CELLS | PAULUS, ERIN VIRGINIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18564485 | COMPOSITION FOR PREVENTING AND TREATING STROKE, COMPRISING HLA HOMOZYGOUS INDUCED PLURIPOTENT STEM CELL-DERIVED NEURAL PRECURSOR CELLS | PAULUS, ERIN VIRGINIA | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18564485 | COMPOSITION FOR PREVENTING AND TREATING STROKE, COMPRISING HLA HOMOZYGOUS INDUCED PLURIPOTENT STEM CELL-DERIVED NEURAL PRECURSOR CELLS | PAULUS, ERIN VIRGINIA | 1631 | §101§102§112 | Non-Final OA | — | Pending | Mar 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialIps Bio Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Erin Virginia Paulus has the most, with 1 of Ips Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
